MeiraGTx Holdings plc
MGTX
Jodie situation report
MeiraGTx Holdings plc's current move is not yet confirmed by its wider market group.
Jodie is checking whether MGTX's market activity is isolated, shared, or spreading through disclosed business relationships.
- Broader participation develops around MGTX.
- A disclosed customer, supplier, or partner begins moving with it.
Who this business touches
The relationships behind MGTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LLYEli Lilly and CompanypartnerMay 14, 2026 ▾
“Eli Lilly and Company Collaboration Agreement On November 7, 2025 (the “Lilly Effective Date”), our affiliates MeiraGTx Ocular UK Limited (“Meira Ocular”), MeiraGTx Limited and MeiraGTx UK II Limited (“Meira UK II”), entered into the Lilly Collaboration Agree…”
VYGRFiling-linked namepartnerMar 30, 2026 ▾
“We are aware of other ALS gene therapies utilizing different treatment mechanisms to treat different genetically defined subsets of ALS patients, as well as gene therapy product candidates being developed for the treatment of Parkinson’s disease, including th…”
Depended on by
OCGNOcugen, Inc.partnerMar 4, 2026 ▾
“We are aware of several companies focusing on gene therapies for various ophthalmic indications including Applied Genetic Technologies Corporation, as acquired by Beacon Therapeutics, Astellas Pharma Inc., MeiraGTx Holdings plc in partnership with Janssen Pha…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MGTX is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.